INCLUSION CRITERIA

   - Histologically-confirmed, bi-dimensionally measurable, recurrent or metastatic
   carcinoma of the breast that is progressive

   - Premenopausal, defined as any of:

      1. Last menstrual period within 3 months, or

      2. Post-hysterectomy without bilateral oophorectomy and with follicle-stimulating
      hormone (FSH) in the premenopausal range, or,

      3. If tamoxifen administered within the past 3 months, plasma estradiol must be in
      the premenopausal range

   - Either positive estrogen and/or progesterone receptor determination by
   Immunohistochemistry (IHC) or competitive binding assay on metastatic disease, or if
   not performed on their metastatic disease a positive result on their primary breast
   cancer specimen.

   - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

   - Granulocytes > 1500/mm^3

   - Platelets > 100,000/mm^3

   - Serum glutamic oxaloacetic transaminase (SGOT) < 2.5 x upper limit of normal

   - Total bilirubin < 1.5 mg/dL

   - May have received irradiation to bony sites of disease for pain control or for
   prevention of fracture. The irradiated site(s) will NOT be evaluable for disease
   response.

   - Must be using effective contraception or not be of childbearing potential

   - Signed written informed consent

INCLUSION CRITERIA

   - Active, unresolved infection

   - Active malignancy other than breast cancer, in situ carcinoma of the cervix, or
   non-melanomatous skin cancers in the past 5 years

   - Prior treatment with an aromatase inhibitor or inactivator

   - Prior treatment with an luteinizing hormone-releasing hormone (LH/RH)
   agonist/antagonist

   - Adjuvant chemotherapy within 6 months of study entry.

   - Received chemotherapy or hormonal therapy in the 3 weeks prior to enrollment

   - Central nervous system metastasis

   - Lymphangitic pulmonary metastasis

   - Pregnant or lactating